Linvoseltamab

Therapeutic indications

Linvoseltamab is indicated for:

Relapsed and refractory multiple myeloma

Population group: only adults (18 years old or older)

Linvoseltamab is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

5 mg on Week 1 Day 1, 25 mg Week 2 Day 1, 200 mg on Week 3 Day 1, 200 mg weekly from Week 4 to Week 13 for 10 treatment doses, and 200 mg on Week 14 and every 2 weeks thereafter

Contraindications

Linvoseltamab is contraindicated in the following cases:

Lactation

Effects on ability to drive and use machines

Live viral vaccines

Live organism vaccines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.